|
|
Upfront Briefing
Big Pharma kept shopping: Angelini agreed to acquire Catalyst Pharmaceuticals for $4.1B, marking its U.S. entry and adding a commercial rare-disease platform.
Roche followed with a PathAI deal worth $750M upfront plus up to $300M in milestones, bringing an AI pathology/CDx platform in-house after a multi-year partnership.
Bayer also moved in ophthalmology, buying Perfuse Therapeutics for $300M upfront and up to $2.15B in milestones for a Phase 2 retinal/eye-disease implant.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,365.1 |
+1.5% |
+7.1% |
| Nasdaq 100 |
28,599.2 |
+2.1% |
+14.9% |
| Russell 2000 |
2,886.8 |
+1.5% |
+10.0% |
| Healthcare (XLV) |
145.4 |
+0.1% |
(6.4%) |
| Biotech (XBI) |
137.7 |
+2.9% |
+9.9% |
| Nasdaq Biotech (NBI) |
6,036.5 |
+2.1% |
+1.8% |
| Clinical Trials (BBC) |
46.0 |
+2.5% |
+12.3% |
|
- Risk-on stayed in control: Nasdaq 100 (+2.1%) led as growth and duration-sensitive equities benefited from a lower-yield / higher-beta tape.
- Biotech finally got paid for beta: XBI (+2.9%) and BBC (+2.5%) outpaced the S&P 500 (+1.5%), helped by a heavy deal tape and renewed appetite for clinical-stage risk.
- Healthcare lagged despite the green tape: XLV (+0.1%) suggests the day’s bid was more cyclicality/growth than classic defensive healthcare rotation.
- Market data: U.S. close Wed 06-May-2026.
The Big 3
|
1
|
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B
|
- Angelini agreed to acquire Catalyst at $31.50/share in cash, valuing the company at ~$4.1B (€3.5B) — a 21% premium to the 22-Apr close and 28% to the 30-day VWAP. The deal brings three FDA-approved rare-disease products (FIRDAPSE in LEMS, AGAMREE in Duchenne, FYCOMPA in epilepsy) that did $589M in 2025 sales and are guided to ~$645M in 2026. Centerview is lead advisor; BNP Paribas / Morgan Stanley co-advisors. Close expected Q3'26.
- Why it matters: At ~7x 2025 sales, this is a premium multiple for a profitable rare-disease cash-flow story — and signals Big Pharma will keep paying up for $500M+ specialty franchises with durable U.S. revenue, not just clinical-stage option value. The transaction was effectively unlocked by today's parallel Catalyst/Hetero patent settlement, which pushes FIRDAPSE generic entry to 2035 and de-risks the largest revenue line. Read-through: comparable U.S.-listed rare-disease commercial names (think Travere, Amneal-style specialty, Harmony, Catalyst's smaller peers) get a fresh comp, and Angelini's first U.S. footprint puts a new strategic buyer on the board for future tuck-ins.
- Source: PR
|
|
2
|
Roche to acquire PathAI for up to $1.05B
|
- Roche entered a definitive merger agreement to acquire PathAI, paying $750M upfront plus up to $300M in milestones. The deal brings PathAI’s digital pathology and AI-powered technology into Roche Diagnostics after a partnership that began in 2021 and expanded in 2024 into AI-enabled companion diagnostic algorithms.
- Why it matters: Roche is effectively buying control of an AI pathology/CDx stack it already knows, which reduces integration risk and gives Roche more vertical leverage across tissue diagnostics, biomarker discovery and trial-enabling companion diagnostics. For investors, the read-through is that diagnostics M&A is shifting from hardware/workflow into data-rich, algorithmic platforms that can become embedded in drug-development decisions.
-
Source:
PR
|
|
3
|
Bayer buys Perfuse Therapeutics in up-to-$2.45B ophthalmology deal |
- Bayer agreed to acquire Perfuse Therapeutics for $300M upfront plus up to $2.15B in development, regulatory and commercial milestones. The deal brings PER-001, a Phase 2 small-molecule endothelin receptor antagonist delivered via a bio-erodible intravitreal implant designed for ~6-month dosing, in development for glaucoma and diabetic retinopathy, with preclinical optionality in dry AMD/geographic atrophy and retinal vein occlusion.
- Why it matters: Bayer needs a next-generation ophthalmology bridge as Eylea faces biosimilar pressure. PER-001 is a hedge with two genuine differentiators — a novel mechanism (vascular/neuroprotection) outside the anti-VEGF lane, and a 6-month sustained-release implant that directly attacks the treatment-burden weakness of monthly anti-VEGF dosing. The economics tell you Bayer is paying for the strategic fit, not yet for the data: $300M upfront vs. $2.15B in milestones means most of the value sits behind Phase 3, and the endothelin pathway has a long history of systemic-tolerability challenges that need to be closed out in pivotal trials.
- Source: Fierce
|
Everything Else that broke
- Sarepta reported Q1 2026: $330.5M net product revenue ($102M ELEVIDYS, $228.6M PMOs); reaffirmed FY26 guide of $1.2–1.4B; reported first Phase 1/2 siRNA data for SRP-1001 (FSHD1) and SRP-1003 (DM1); submitted sNDAs to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval. — PR
- Nuvation Bio: FDA accepted sNDA for IBTROZI (taletrectinib) with updated duration-of-response data in advanced ROS1+ NSCLC; target action date Jan 4, 2027. — RTT
- Mirum's Phase 2b VISTAS study of volixibat in primary sclerosing cholangitis met its primary endpoint in the moderate-to-severe itch cohort (n=111); pre-NDA meeting planned for summer 2026, NDA filing in H2'26. — PR
- Revolution Medicines: Phase 1/2 daraxonrasib pancreatic cancer data published in NEJM, ahead of the ongoing Phase 3 program — supportive backdrop for the Merck takeout chatter that's still dangling. — PR
- Mineralys reiterated that FDA accepted the lorundrostat NDA and assigned a Dec. 22, 2026 PDUFA date; the original NDA acceptance was announced in March, so this is a catalyst-calendar reminder rather than new regulatory action. — PR
- Catalyst settles FIRDAPSE patent case with Hetero, with a generic license starting in 2035. — PR
- BioSpace flagged that three top FDA and CDC roles were filled by 15 different people in less than 18 months. — BioSpace
- Vaxcyte said OPUS Phase 3 enrollment is complete for VAX-31 alongside its Q1 results update. — PR
- Zealand Pharma launched a $200M (DKK 1.3B) share buyback program. — PR
- TerraPower Isotopes broke ground on an actinium-225 manufacturing facility in Philadelphia. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1B. — PR
-
Roche to acquire PathAI for $750M upfront plus up to $300M in milestones, bringing an AI pathology and companion-diagnostics platform in-house. — PR
-
Bayer to acquire Perfuse Therapeutics for $300M upfront and up to $2.15B in milestones. — Fierce
-
GSK licenses SiranBio’s Phase 1 ALK7-targeting oligonucleotide SA030 for metabolic/vascular disease outside Greater China for $55M upfront and up to $1B in milestones. — Fierce
-
Ribo and Boehringer Ingelheim report progress on siRNA MASH program. — PR
VC / Private Financings
- CellCentric raised an oversubscribed $220M Series D to advance p300/CBP inhibitor inobrodib through registration-enabling myeloma trials and preserve IPO optionality. Led by Venrock Healthcare Capital Partners, with Fidelity Management & Research, Sofinnova Partners and HBM Healthcare joining existing investors including RA Capital, Forbion and Pfizer. — Fierce
- LTZ Therapeutics raised an oversubscribed $38M financing to advance its Universal Myeloid Cell Engager pipeline, including Phase 1 LTZ-301 in r/r NHL. Led by GL Ventures, with substantial participation from a sovereign wealth fund and continued support from existing shareholders. — PR
IPOs / Follow-Ons
- InflaRx priced a $150M underwritten offering of 75M ordinary shares at $2.00/share, with participation from TCGX, Farallon, Sirenia, Columbia Threadneedle, Great Point, ADAR1, Coastlands and Squadron. — PR
- Viridian priced upsized concurrent offerings for aggregate gross proceeds of $350M, following its positive REVEAL-2 chronic TED data. — PR
Academic Corner - Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. — NEJM
- Bridging boundaries: making drug repurposing the new normal. — Nature RDD
- Treatment of Anterior Cruciate Ligament Rupture. — JAMA
|
|
That’s it for today — Big Pharma brought the shopping bags, biotech brought the receipts. See you tomorrow.
BioBucks Team
|
|
|
